CASE REPORT
Shulman disease (eosinophilic fasciitis) in X-linked agammaglobulinemia
 
More details
Hide details
 
Submission date: 2015-07-13
 
 
Final revision date: 2015-08-27
 
 
Acceptance date: 2015-09-03
 
 
Publication date: 2016-08-02
 
 
Pol J Pathol 2016;67(2):183-188
 
KEYWORDS
TOPICS
ABSTRACT
X-linked agammaglobulinemia (XLA) diagnosed in the first year of life is an immunodeficiency with a life-long indication for substitution of immunoglobulins, due to lack of B lymphocytes in the periphery. The decrease of bacterial infection frequency and severity is an effect of immunoglobulin replacement. However, in the majority of patients bronchiectasis and chronic sinusitis with an overgrown mucous membrane develop despite regular substitution. Autoimmune diseases as co-existing diseases in XLA are noted in a few patients presenting symptoms associated with arthritis, scleroderma and myositis. Our patient was diagnosed with XLA in the first year of life, followed by regular substitution of immunoglobulins. The symptoms of pain, edema of muscles of the right shank with skin edema and discoloration after mild injury were noted in a 13-year-old boy. Shulman disease was diagnosed after 6 months of symptoms, based on histopathology of muscle and skin biopsy. Before the diagnosis, non-steroid anti-inflammatory drugs (NSAID) were used with a transient effect. After the diagnosis, therapy included steroids, immunoglobulins in a high dose and immunosuppression, with improvement of clinical symptoms. During methotrexate (MTX) therapy the patient developed two episodes of pneumonia, so mycophenolate mofetil (MMF) was used, with a similar effect. Now, with this therapy, the symptoms are mild and stable without progression.
REFERENCES (22)
1.
Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol 2010; 125 (2 Suppl 2): S182-194.
 
2.
Al-Herz W, Bousfiha A, Casanova J-L, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol 2011; 54: 1-21.
 
3.
Pac M, Mikołuć B, Pietrucha B, et al. Clinical and immunological analysis of patients with X-linked agammaglobulinemia: single center experience. Centr Eur J Immunol 2013; 38: 367-371.
 
4.
Pituch-Noworolska A, Zwonarz K, Błaut-Szlósarczyk A, et al. T lymphocytes and NK cells in X-linked agammaglobulinemia. Przegląd Lekarski 2013; 70: 1048-1050.
 
5.
Smith CIE, Conley ME. X-linked agammaglobulinemia and autosomal recessive agammaglobulinemia. In: Primary immunodeficiency diseases. Ochs HD, Smith CIE, Puck JM (eds). University Press, Oxford, 2014; 299-323.
 
6.
Martini H, Enright V, Petro M, et al. Importance of B cell co-stimulation in CD4+ T cell differentiation: X-linked agammaglobulinemia, a human model. Clin Exp Imunol 2011; 164: 381-387.
 
7.
Amedei A, Romagnani Ch, Benagiano M, et al. Preferential Th1 profile of T cell responses in X-linked (Bruton’s) agammaglobulinemia. Eur J Immunol 2001; 31: 1927-1934.
 
8.
Aghamohammadi A, Fiorini M, Moin M, et al. Clinical, immunological and molecular characteristics of 37 Iranian patients with X-linked agammaglobulinemia. Int Arch Allergy Immunol 2006; 141: 408-412.
 
9.
Quartier P, Debre M, De Blic J, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective study of 31 patients.
 
10.
J Pediatr 1999; 134: 589-563.
 
11.
Hernandez-Trujillo VP, Scalchunes Ch, Cunningham-Rundles Ch, et al. Autoimmunity and inflammation in X-linked agammaglobulinemia. J Clin Immunol 2014; 34: 627-632.
 
12.
Arason GJ, Jorgensen GH, Ludviksson BR. Primary immunodeficiency and autoimmunity: lesson from human diseases. Scand J Immunol 2010; 71: 317-328.
 
13.
Todoric K, Koontz JB, Mattox D, et al. Autoimmunity in immunodeficiency. Curr Allergy Asthma Rep 2013; 13: 361-370.
 
14.
Verbruggen G, De Backer S, Deforce D, et al. X-linked agammaglobulinemia and rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1075-1078.
 
15.
Machado P, Santos A, Faria E, et al. Arthritis and X-linked agammaglobulinemia. Acta Rheumatol Port 2008; 33: 464-472.
 
16.
Loupasakis K, Derk CT. Eosinophilic fasciitis in a pediatric patient. J Clin Rheumatol 2010; 16: 129-131.
 
17.
Pinal-Fernandez I, Selva-O’Callaghan A, Grau JM. Diagnosis and classification of eosinophilic fasciitis. Autoimmunity Rev 2014; 3: 379-382.
 
18.
Lebeaux D, Frances C, Barete S, et al. Eosinophilic fasciitis (Shulman disease). Rheumatology (Oxford) 2012; 51: 557-561.
 
19.
Nashel J, Steen V. The use of an elevated aldolase in diagnosing and managing eosinophilic fasciits. Clin Rheumatol 2015; 34: 1481-1484.
 
20.
Lebeaux D, Sene D. Eosinophilic fasciitis (Shulman disease). Best Pract Res Clin Rheumatol 2012; 26: 449-458.
 
21.
Berianu F, Cohen MD, Abril A, et al. Eosinophilic faciitis: clinical characteristics and response to methotrexate. Int J Rheumatic Dis 2014; 18: 91-98.
 
22.
Servy A, Clerici T, Malines C, et al. Eosinophilic fasciitis: a rare skin sclerosis. Patholog Res Int 2011; 2011: 716935.
 
eISSN:2084-9869
ISSN:1233-9687
Journals System - logo
Scroll to top